Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06263114 · ClinicalTrials.gov registry record
Correlation of Blood Gene Expression (TruGraf Liver) With Liver Biopsy in Pediatric Liver Transplant Recipients
A clinical trial, sponsored by Children's Mercy Hospital Kansas City.
- Terminated
- Registry status
- 16
- Enrollment target
NCT06263114 is a clinical trial that was terminated before completion, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 16 participants.
The verdict
NCT06263114 was terminated before completion, sponsored by Children's Mercy Hospital Kansas City.
- TERMINATED
- Registry status
- 16 participants
- Enrollment target
Study Summary
Liver transplant rejection is when the body's immune system attacks and damages the liver of a transplant recipient. Currently the best way to see if that is happening is with a liver biopsy. The purpose of this research study is to see if a simple blood test can diagnose if a transplanted liver is being rejected.
Interventions
- DIAGNOSTIC_TEST TruGraf® Liver gene expression panel (GEP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2024-01-01 |
| Est. Completion | 2025-02-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06263114
The ClinicalTrials.gov registry entry for NCT06263114 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Mercy Hospital Kansas City, which has 184 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TruGraf® Liver gene expression panel (GEP) is the first listed.
NCT06263114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06263114 about?
NCT06263114 is a clinical study titled "Correlation of Blood Gene Expression (TruGraf Liver) With Liver Biopsy in Pediatric Liver Transplant Recipients". Liver transplant rejection is when the body's immune system attacks and damages the liver of a transplant recipient. Currently the best way to see if that is happening is with a liver biopsy. The purpose of this research study is to see if a simple blood test can diagnose if a transplanted liver is ...
What is the current status of trial NCT06263114?
This trial is currently terminated. The enrollment target is 16 participants. The study started on 2024-01-01. Estimated completion is 2025-02-07.
What interventions are being tested in trial NCT06263114?
The interventions under investigation include: TruGraf® Liver gene expression panel (GEP) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06263114?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.